Press Release September 13, 2020

Gilead Sciences to Acquire Immunomedics

The Life Sciences team advised Centerview Partners, financial advisor to Immunomedics, Inc. (NASDAQ: IMMU), on the definitive agreement pursuant to which Gilead Sciences, Inc. (Nasdaq: GILD) will acquire Immunomedics for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both the Gilead and Immunomedics Boards of Directors and is anticipated to close during the fourth quarter of 2020.
 
The agreement will provide Gilead with TrodelvyTM (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in April for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Immunomedics plans to submit a supplemental Biologics License Application (BLA) to support full approval of Trodelvy in the United States in the fourth quarter of 2020. Immunomedics is also on track to file for regulatory approval in Europe in the first half of 2021.
 
Centerview is a leading independent investment banking and advisory firm. The firm provides advice on mergers and acquisitions, financial restructurings, valuation, and capital structure to companies, institutions and governments. Since the founding of Centerview in 2006, the firm has advised on nearly $3 trillion of transactions. Immunomedics is a leading biopharmaceutical company in the area of antibody-drug conjugates, committed to help transform the lives of people with hard-to-treat cancers.
 
The Goodwin team was led by Stuart Cable, James Matarese, and Blake Liggio
 
For more details, read the press release